查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球 DNA 診斷市場：市場規模、佔有率、趨勢：按產品、按技術、按檢體、按應用、按最終用戶、按地區 - 預測至 2029 年
市場調查報告書
商品編碼
1511375

全球 DNA 診斷市場：市場規模、佔有率、趨勢：按產品、按技術、按檢體、按應用、按最終用戶、按地區 - 預測至 2029 年

DNA Diagnostics Market Size, Share & Trends by Product, Technology, Application (Infectious Disease, Oncology), Specimen - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 334 Pages | 訂單完成後即時交付

價格
簡介目錄

預計到 2024 年，全球 DNA 診斷市場規模將達到 133 億美元，到 2029 年預計將達到 212 億美元，預測期內複合年成長率為 9.7%。

DNA 診斷市場的成長主要是由慢性病和感染疾病患者病率的增加、個人化醫療 DNA 診斷的進步以及醫療保健相關企業的資金籌措的。個人化藥物可以幫助做出明智的臨床決策並降低不利事件的風險。因此，對個人化醫療不斷成長的需求預計將為未來幾年在 DNA 診斷市場營運的公司提供巨大的成長機會。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（十億美元）
按細分市場 按產品、按技術、按檢體、按應用、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、中東/非洲、拉丁美洲、海灣合作理事會國家

DNA 診斷市場分為試劑/套件、儀器以及服務和軟體。頻繁需要試劑和套件，導致經常性成本，這種經常性採購需求是市場成長的關鍵驅動力之一。試劑和套件滿足不同檢測需求的多功能性有助於其在預測期內的廣泛使用和市場需求。

依技術分類，DNA 診斷市場分為聚合酵素鏈鎖反應(PCR)、微陣列、原位雜合反應、定序技術、質譜和其他技術。 PCR 技術經過了廣泛的標準化，以確保不同實驗室和平台的結果一致且可靠。目前，PCR 因其易用性、成本效益和快速測量時間（4-6 小時）而成為診斷中使用最廣泛的技術之一。此外，小型 PCR 設備可能需要很少的維護。這些因素促進了該細分市場的成長。

依檢體，DNA診斷市場分為血液、血清、血漿、尿液和其他檢體。血液採集和處理程序經過廣泛標準化，以確保一致的檢體品質和測試結果的可靠性。標準化方案和品管措施提高了對血液檢體進行 DNA 診斷測試的準確性和可重複性。 2023年DNA診斷市場，哪個領域將佔最大市場佔有率？

DNA 診斷市場按應用細分為感染疾病診斷、腫瘤檢測、產前診斷、胚胎著床前診斷、肌源性疾病和其他應用。腫瘤學檢測需求的激增是由多種因素推動的，這些因素正在改變癌症診斷和治療的模式。 DNA 診斷測試使醫生能夠檢查遺傳物質是否易患疾病，並及早診斷癌症等疾病。該領域的成長也受到技術進步和癌症發病率增加的推動。

按最終用戶分類，DNA 診斷市場分為醫院/診所、診斷實驗室和其他最終用戶。醫院擴大將診斷測試委託給診斷實驗室，以減少與實驗室管理相關的成本和技術問題。許多中小型醫院和診所都採用了這一趨勢，推動了這一領域的成長。

該報告研究了全球 DNA 診斷市場，包括按產品、技術、檢體、應用、最終用戶、地區和參與市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
  • 波特五力分析
  • 監管分析
  • 技術分析
  • 貿易分析
  • 專利分析
  • 2024-2025年重大會議和活動
  • PESTLE分析
  • 影響客戶業務的趨勢/干擾
  • 主要相關人員和採購標準
  • 投資金籌措場景

第6章 DNA 診斷市場，依產品分類

  • 介紹
  • 試劑/套件
  • 裝置
  • 服務軟體

第7章 DNA 診斷市場（依技術）

  • 介紹
  • 聚合酵素鏈鎖反應
  • 微陣列
  • 原位雜合反應
  • 定序
  • 質譜
  • 其他

第8章 DNA 診斷市場（按檢體）

  • 介紹
  • 血液、血清、血漿
  • 尿
  • 其他

第9章 DNA 診斷市場，依應用

  • 介紹
  • 感染疾病診斷
  • 腫瘤檢查
  • 肌原性疾病
  • 產前
  • 胚胎著床前
  • 其他

第 10 章 DNA 診斷市場（依最終用戶）

  • 介紹
  • 診斷實驗室
  • 醫院和診所
  • 其他

第 11 章 DNA 診斷市場（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
  • 海灣合作理事會國家

第12章競爭格局

  • 概述
  • 主要參與企業的策略/秘密
  • 收益分析
  • 市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第13章 公司簡介

  • 主要參與企業
    • DANAHER
    • ILLUMINA, INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • BIOMERIEUX
    • HOLOGIC, INC.
    • ABBOTT LABORATORIES
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN
    • REVVITY, INC.
    • MYRIAD GENETICS, INC.
    • SIEMENS HEALTHINEERS AG
  • 其他公司
    • BECTON, DICKINSON AND COMPANY
    • GRIFOLS, SA
    • QUIDELORTHO CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • DIASORIN SPA
    • EXACT SCIENCES CORPORATION
    • GENETIC SIGNATURES
    • BIOCARTIS
    • TBG DIAGNOSTICS LIMITED
    • VELA DIAGNOSTICS
    • AMOY DIAGNOSTICS CO., LTD.
    • MOLBIO DIAGNOSTICS PVT. LTD.

第14章附錄

簡介目錄
Product Code: MD 9069

The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period. Growth in the DNA diagnostics market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in DNA diagnostics for personalized medicine, and increasing funding by healthcare-based companies. Personalized medicines help in making informed clinical decisions and alleviating the risk of adverse events. Thus, the increasing demand for personalized medicines is expected to offer significant growth opportunities for players operating in the DNA diagnostics market in the coming years.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Billion)
SegmentsBy Offering, Technology, Specimen, Application, End User, and region
Regions coveredNorth America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries

"The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period"

Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.

"The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period."

Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.

"The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen"

Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.

"The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period".

Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.

"The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user".

Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.

"The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period"

The global DNA diagnostics market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 35%, Europe - 26%, Asia Pacific - 24%, Latin America - 12%, Middle East & Africa - 2%, and the GCC Countries - 1%

Lists of Companies Profiled in the Report:

Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).

Research Coverage:

In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).

The report's coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Rising incidence of chronic and infectious diseases, Rising focus on R&D and increased funding by healthcare-based companies, Growing demand for early disease diagnosis an dpersonalized medicine in developing countries, and Technological advancements in DNA diagnostics industry), challenges (Changing regulatory landscape for IVD and DNA diagnostics in US and European Union, Operational barriers and shortage of skills across major markets, and Introductio of alternatives technologies for disease detection and diagnosis), opportunities (Growing significance of companion diagnostics in drug development process, Increasing growth opportunities for DNA diagnostic companies in emerging economies, Advancements in bioinformatics and artificial intelligence in DNA diagnostics and Expansion of direct-to-consumer (DTC) genetic tetsing), and restraints (Unfavourable reimbursement scenario for diagnostic companies, High cost of DNA diagnostic instruments, and Ethical and privacy concerns associated with DNA diagnosis) influencing the growth of the in DNA diagnostics market.
  • Product Development/Innovation: Detailed insights on research & development activities and new product launches and approvals in the DNA diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the DNA diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the DNA diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are among others, in the DNA diagnostics market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 REGIONAL SEGMENTATION
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 DNA DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 6 DNA DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ON DNA DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
    • FIGURE 9 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 DNA DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 GEOGRAPHIC SNAPSHOT OF DNA DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 DNA DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY AND COUNTRY (2023)
    • FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • 4.3 DNA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN DNA DIAGNOSTICS MARKET FROM 2024 TO 2029
  • 4.4 DNA DIAGNOSTICS MARKET: REGIONAL MIX (2024-2029)
    • FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 DNA DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases
    • FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
      • 5.2.1.2 Rising focus on R&D and increased funding by healthcare companies
      • 5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries
      • 5.2.1.4 Technological advancements in DNA diagnostics industry
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
      • 5.2.2.2 High cost of DNA diagnostic instruments
      • 5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics in drug development process
      • 5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies
      • 5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics
      • 5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union
      • 5.2.4.2 Operational barriers and shortage of skills across major markets
      • 5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
  • 5.3 PRICING ANALYSIS
    • 5.3.1 PRICING ANALYSIS, BY REGION
    • TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023
    • 5.3.2 PRICING ANALYSIS, BY PRODUCT
    • TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021-2023
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 DNA DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 23 DNA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
    • 5.6.1 DNA DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 DNA DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 24 DNA DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 REGULATORY ANALYSIS
    • 5.8.1 NORTH AMERICA
      • 5.8.1.1 US
      • 5.8.1.2 Canada
    • 5.8.2 EUROPE
    • TABLE 5 EUROPE: CLASSIFICATION OF DEVICES
    • 5.8.3 ASIA PACIFIC
      • 5.8.3.1 China
      • 5.8.3.2 Japan
    • TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.8.3.3 India
    • 5.8.4 LATIN AMERICA
      • 5.8.4.1 Brazil
      • 5.8.4.2 Mexico
    • 5.8.5 MIDDLE EAST
    • 5.8.6 AFRICA
    • 5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Polymerase chain reaction
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Sequencing technology
      • 5.9.2.2 DNA microarrays
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Isothermal nucleic acid amplification technology
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2023 (USD MILLION)
    • TABLE 13 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2023 (USD MILLION)
  • 5.11 PATENT ANALYSIS
    • FIGURE 25 PATENT ANALYSIS FOR DNA DIAGNOSTICS (JANUARY 2013-DECEMBER 2023)
    • 5.11.1 LIST OF MAJOR PATENTS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2024-2025
    • TABLE 14 DNA DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2024-2025
  • 5.13 PESTLE ANALYSIS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.14.1 REVENUE SHIFT IN DNA DIAGNOSTICS MARKET
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS (%)
    • 5.15.2 BUYING CRITERIA
    • FIGURE 27 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
    • TABLE 16 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
  • 5.16 INVESTMENT & FUNDING SCENARIO
    • FIGURE 28 DNA DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO

6 DNA DIAGNOSTICS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
    • TABLE 17 DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 18 PRICE OF DNA DIAGNOSTIC PRODUCTS (2023)
  • 6.2 REAGENTS & KITS
    • 6.2.1 RECURRENT PURCHASE FOR DIAGNOSTICS TO PROPEL MARKET
    • TABLE 19 DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 20 NORTH AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 21 EUROPE: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 23 LATIN AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
    • TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
    • TABLE 25 DNA DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 26 NORTH AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 27 EUROPE: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 29 LATIN AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH
    • TABLE 30 DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 31 NORTH AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 EUROPE: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 34 LATIN AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 35 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • 7.2 POLYMERASE CHAIN REACTION
    • 7.2.1 GROWING USE OF PCR IN GENOMICS TO DRIVE MARKET
    • TABLE 36 DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 37 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 EUROPE: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 40 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 MICROARRAY
    • 7.3.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
    • TABLE 41 DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 42 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 43 EUROPE: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 45 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 IN SITU HYBRIDIZATION
    • 7.4.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
    • TABLE 46 DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 47 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 48 EUROPE: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 SEQUENCING
    • 7.5.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
    • TABLE 51 DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 52 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 53 EUROPE: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 54 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.6 MASS SPECTROSCOPY
    • 7.6.1 TECHNOLOGICAL ADVANCEMENTS IN MASS SPECTROMETERS TO DRIVE ADOPTION
    • TABLE 56 DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 57 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 EUROPE: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 60 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.7 OTHER TECHNOLOGIES
    • TABLE 61 DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 62 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 65 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)

8 DNA DIAGNOSTICS MARKET, BY SPECIMEN

  • 8.1 INTRODUCTION
    • TABLE 66 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 67 DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 68 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 EUROPE: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 71 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 URINE
    • 8.3.1 NONINVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
    • TABLE 72 DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 73 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 EUROPE: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 OTHER SPECIMENS
    • TABLE 77 DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 78 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 79 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)

9 DNA DIAGNOSTICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 82 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 9.2 INFECTIOUS DISEASE DIAGNOSTICS
    • TABLE 83 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 84 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 86 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.1 HEPATITIS
      • 9.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive growth
    • TABLE 89 DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 90 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 91 EUROPE: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.2 HIV
      • 9.2.2.1 Increasing prevalence of HIV to propel market
    • TABLE 94 DNA DIAGNOSTICS MARKET FOR HIV, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 95 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 96 EUROPE: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 98 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.3 CT/NG
      • 9.2.3.1 Increasing prevalence of CT/NG infections to support market growth
    • TABLE 99 DNA DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 100 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 101 EUROPE: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 103 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.4 HPV
      • 9.2.4.1 Technological advancements for preventing HPV infections to drive market
    • TABLE 104 DNA DIAGNOSTICS MARKET FOR HPV, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 105 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 EUROPE: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 107 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 108 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
    • 9.2.5 OTHER INFECTIOUS DISEASES
    • TABLE 109 DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 110 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 113 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 ONCOLOGY TESTING
    • 9.3.1 GROWING SIGNIFICANCE OF PRECISION MEDICINE AND PERSONALIZED APPROACHES IN CANCER CARE TO DRIVE MARKET
    • TABLE 114 DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 115 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 EUROPE: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.4 MYOGENIC DISORDERS
    • 9.4.1 DIAGNOSIS OF VARIOUS MYOGENIC DISORDERS THROUGH DNA TESTING TO PROPEL MARKET
    • TABLE 119 DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 120 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 EUROPE: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 123 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.5 PRENATAL
    • 9.5.1 INCREASING DEMAND FOR EARLY DETECTION OF GENETIC DISORDERS TO BOOST MARKET GROWTH
    • TABLE 124 DNA DIAGNOSTICS MARKET FOR PRENATAL, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 125 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 126 EUROPE: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 127 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.6 PREIMPLANTATION
    • 9.6.1 GROWING NUMBER OF FERTILITY CLINICS AND IVF CENTERS TO PROPEL MARKET
    • TABLE 129 NUMBER OF PREIMPLANTATION TESTS PERFORMED, BY COUNTRY, 2022-2029
    • TABLE 130 DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 131 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 132 EUROPE: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 134 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.7 OTHER APPLICATIONS
    • TABLE 135 DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 136 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 137 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

10 DNA DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 140 DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.2 DIAGNOSTIC LABORATORIES
    • 10.2.1 INCREASED OUTSOURCING OF DIAGNOSTIC TESTS BY HOSPITALS TO DRIVE MARKET
    • TABLE 141 DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 142 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 143 EUROPE: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 145 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.3 HOSPITALS & CLINICS
    • 10.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST GROWTH
    • TABLE 146 DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 147 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 148 EUROPE: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 150 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.4 OTHER END USERS
    • TABLE 151 DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 152 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 153 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 154 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 155 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

11 DNA DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 156 DNA DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: DNA DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 157 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 158 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 159 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 160 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 161 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 162 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 163 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
    • TABLE 164 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 165 US: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 166 US: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 167 US: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 168 US: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 169 US: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 US: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Rising prevalence of cancer and availability of healthcare funding to support market growth
    • TABLE 171 CANADA: CANCER DEATHS, BY TYPE, 2024 (%)
    • TABLE 172 CANADA: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 173 CANADA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 174 CANADA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 175 CANADA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 176 CANADA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 177 CANADA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 178 CANADA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 179 EUROPE: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 180 EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 181 EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 182 EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 183 EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 184 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 185 EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.1 EUROPE: RECESSION IMPACT
    • 11.3.2 GERMANY
      • 11.3.2.1 Favorable government policies and rising per capita disposable income to propel market
    • TABLE 186 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 187 GERMANY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 188 GERMANY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 189 GERMANY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 190 GERMANY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 191 GERMANY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 192 GERMANY: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Growing number of accredited diagnostic laboratories to drive market
    • TABLE 193 UK: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 194 UK: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 195 UK: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 196 UK: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 197 UK: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 198 UK: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
    • TABLE 199 FRANCE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 200 FRANCE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 201 FRANCE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 202 FRANCE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 203 FRANCE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 204 FRANCE: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Adoption of advanced diagnostic technologies to support market growth
    • TABLE 205 ITALY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 206 ITALY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 207 ITALY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 208 ITALY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 209 ITALY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 ITALY: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
    • TABLE 211 SPAIN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 212 SPAIN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 213 SPAIN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 214 SPAIN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 215 SPAIN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 216 SPAIN: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 217 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 218 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 219 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 220 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 221 REST OF EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 222 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 30 ASIA PACIFIC: DNA DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 223 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 224 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 225 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 226 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 227 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 228 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 229 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 11.4.2 JAPAN
      • 11.4.2.1 Universal healthcare reimbursement policy to support market growth
    • TABLE 230 JAPAN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 231 JAPAN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 232 JAPAN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 233 JAPAN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 234 JAPAN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 JAPAN: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.3 CHINA
      • 11.4.3.1 Rapid economic growth and greater public access to modern healthcare to drive market
    • TABLE 236 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 237 CHINA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 238 CHINA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 239 CHINA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 240 CHINA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 241 CHINA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 242 CHINA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.4 INDIA
      • 11.4.4.1 Increased private & public investments and large patient population to drive market
    • TABLE 243 INDIA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 244 INDIA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 245 INDIA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 246 INDIA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 247 INDIA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 248 INDIA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 249 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 250 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 251 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 252 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 253 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 254 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.5 LATIN AMERICA
    • TABLE 255 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 256 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 257 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 258 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 259 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 260 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 261 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
    • 11.5.2 BRAZIL
      • 11.5.2.1 Improving healthcare infrastructure and stringent regulations to drive market
    • TABLE 262 BRAZIL: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 263 BRAZIL: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 264 BRAZIL: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 265 BRAZIL: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 266 BRAZIL: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 267 BRAZIL: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.3 MEXICO
      • 11.5.3.1 Improving accessibility and affordability of healthcare services to aid market growth
    • TABLE 268 MEXICO: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 269 MEXICO: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 270 MEXICO: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 271 MEXICO: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 272 MEXICO: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 273 MEXICO: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.4 REST OF LATIN AMERICA
    • TABLE 274 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 275 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 276 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 277 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 278 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 279 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
    • TABLE 280 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
    • TABLE 281 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 282 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 283 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 284 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 285 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 286 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 11.7 GCC COUNTRIES
    • 11.7.1 INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO DRIVE MARKET
    • TABLE 287 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
    • TABLE 288 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 289 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
    • TABLE 290 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 291 GCC COUNTRIES: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 292 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.7.2 GCC COUNTRIES: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN DNA DIAGNOSTICS MARKET
    • TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DNA DIAGNOSTICS MARKET
  • 12.3 REVENUE ANALYSIS
    • FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN DNA DIAGNOSTICS MARKET, 2021-2023 (USD MILLION)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 32 DNA DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
    • TABLE 294 DNA DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 33 DNA DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
    • TABLE 295 DNA DIAGNOSTICS MARKET: COMPANY FOOTPRINT
      • 12.5.5.2 Offering footprint
    • TABLE 296 DNA DIAGNOSTICS MARKET: OFFERING FOOTPRINT
      • 12.5.5.3 Technology footprint
    • TABLE 297 DNA DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
      • 12.5.5.4 End-user footprint
    • TABLE 298 DNA DIAGNOSTICS MARKET: END-USER FOOTPRINT
      • 12.5.5.5 Region footprint
    • TABLE 299 DNA DIAGNOSTICS MARKET: REGION FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 34 DNA DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • TABLE 300 DNA DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • 12.7 VALUATION & FINANCIAL METRICS
    • FIGURE 35 EV/EBITDA OF KEY VENDORS
    • FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 12.8 BRAND/PRODUCT COMPARISON
    • FIGURE 37 DNA DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 301 DNA DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • 12.9.2 DEALS
    • TABLE 302 DNA DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MAY 2024
    • 12.9.3 EXPANSIONS
    • TABLE 303 DNA DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-MAY 2024
    • 12.9.4 OTHER DEVELOPMENTS
    • TABLE 304 DNA DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024

13 COMPANY PROFILES

  • (Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats) **
  • 13.1 KEY PLAYERS
    • 13.1.1 DANAHER
    • TABLE 305 DANAHER: COMPANY OVERVIEW
    • FIGURE 38 DANAHER: COMPANY SNAPSHOT (2023)
    • TABLE 306 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 307 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 308 DANAHER: DEALS, JANUARY 2021-MAY 2024
    • 13.1.2 ILLUMINA, INC.
    • TABLE 309 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2023)
    • TABLE 310 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 311 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 312 ILLUMINA, INC.: DEALS, JANUARY 2021-MAY 2024
    • TABLE 313 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021-MAY 2024
    • TABLE 314 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 315 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 316 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 317 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 318 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-MAY 2024
    • 13.1.4 BIOMERIEUX
    • TABLE 319 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 41 BIOMERIEUX: COMPANY SNAPSHOT (2023)
    • TABLE 320 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 321 BIOMERIEUX: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • 13.1.5 HOLOGIC, INC.
    • TABLE 322 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 323 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 324 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 325 HOLOGIC, INC.: DEALS, JANUARY 2021-MAY 2024
    • 13.1.6 ABBOTT LABORATORIES
    • TABLE 326 ABBOTT LABORATORIES: COMPANY OVERVIEW
    • FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
    • TABLE 327 ABBOTT LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 328 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 329 ABBOTT LABORATORIES: DEALS, JANUARY 2021-MAY 2024
    • 13.1.7 THERMO FISHER SCIENTIFIC INC.
    • TABLE 330 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 331 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 332 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-MAY 2024
    • 13.1.8 QIAGEN
    • TABLE 333 QIAGEN: COMPANY OVERVIEW
    • FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023)
    • TABLE 334 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 335 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 336 QIAGEN: DEALS, JANUARY 2021-MAY 2024
    • 13.1.9 REVVITY, INC.
    • TABLE 337 REVVITY, INC.: COMPANY OVERVIEW
    • FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 338 REVVITY, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 339 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 340 REVVITY, INC.: DEALS, JANUARY 2021-MAY 2024
    • 13.1.10 MYRIAD GENETICS, INC.
    • TABLE 341 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
    • FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 342 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 343 MYRIAD GENETICS, INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 344 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021-MAY 2024
    • 13.1.11 SIEMENS HEALTHINEERS AG
    • TABLE 345 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
    • TABLE 346 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • *Details on Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 BECTON, DICKINSON AND COMPANY
    • 13.2.2 GRIFOLS, S.A.
    • 13.2.3 QUIDELORTHO CORPORATION
    • 13.2.4 AGILENT TECHNOLOGIES, INC.
    • 13.2.5 DIASORIN S.P.A.
    • 13.2.6 EXACT SCIENCES CORPORATION
    • 13.2.7 GENETIC SIGNATURES
    • 13.2.8 BIOCARTIS
    • 13.2.9 TBG DIAGNOSTICS LIMITED
    • TABLE 347 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
    • 13.2.10 VELA DIAGNOSTICS
    • TABLE 348 VELA DIAGNOSTICS: COMPANY OVERVIEW
    • 13.2.11 AMOY DIAGNOSTICS CO., LTD.
    • TABLE 349 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
    • 13.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
    • TABLE 350 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS